EU/3/16/1738

Table of contents

About

On 14 October 2016, orphan designation (EU/3/16/1738) was granted by the European Commission to F2G Ltd, United Kingdom, for 2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-{4-[4-(5-fluoro-pyrimidin-2-yl)piperazin-1-yl]-phenyl}-2-oxo-acetamide (also known as F901318) for the treatment of invasive aspergillosis.

This medicine is now known as olorofim.

Key facts

Active substance
2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-{4-[4-(5-fluoro-pyrimidin-2-yl)piperazin-1-yl]-phenyl}-2-oxo-acetamide (also known as F901318)(olorofim)
Disease / condition
Treatment of invasive aspergillosis
Date of decision
14/10/2016
Outcome
Positive
Orphan decision number
EU/3/16/1738

Sponsor's contact details

F2G Ltd
Lankro Way, Eccles
Manchester
M30 0LX
United Kingdom
Tel. +44 (0)1617 851 270
Fax +44 (0)1617 851 273
E-mail: contact@f2g.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating